Xspray Pharma – Capital Markets Day Invitation

Press release 2022-05-06

Xspray Pharma hereby invites investors, analysts, media representatives and other stakeholders to a Capital Markets Day, Tuesday May 24, 2022 at 10.00-12.00 CET, followed by lunch, at Hallvarsson & Halvarson, Sveavägen 20, Stockholm.

The Capital Markets Day will be webcast between 10.00-12.00 CET. After the Capital Markets Day an on-demand replay will be available on the companys website. The presentation will be held in English and will cover an update on Xspray Pharma’s operations, technology, financials and strategy. It will also cover the present view on the US market and the strategy to enter the US market. There will be a Q&A session with the opportunity to ask questions. Xspray Pharma will be represented by the CEO Per Andersson, and CFO Kerstin Hasselgren together with other senior executives.

RSVP by May 20 via info@xspray.com.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com